hHv1 Polypeptide Modulators

Tech ID: 30417 / UC Case 2019-915-0

Brief Description

A novel class of hHv1 polypeptide modulators designed for selective modulation of hHv1 voltage gated channels, offering new avenues in medical treatment.

Suggested uses

  • Inflammatory disease treatment, including acute lung injury/ARDS, stroke, and neuropathic pain
  • Birth Control through inhibition of sperm maturation
  • Autoimmune therapies by reducing ROS in white blood cells
  • Cancer therapeutics focusing on tumor reduction

Features/Benefits

  • Selectively targets only hHv1 voltage gated channels
  • Capable of both inhibiting and activating modulators
  • Cell type specific response, ensuring targeted treatment
  • Monomeric peptide effectively inhibits ROS and inflammatory cytokines
  • Dimeric peptide blocks the hHv1 channel in both open and closed states with high affinity

Full Description

Developed by researchers at the University of California, Irvine, this novel class of hHv1 polypeptide modulators selectively targets hHv1 voltage gated channels, a key player in various cellular functions. Unlike existing treatments, these modulators do not affect other voltage gated channels, providing a targeted approach to treating diseases. With applications ranging from birth control to cancer therapeutics, these modulators represent a significant advancement in medical research.

State Of Development

Pre-clinical studies

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 11,274,130 03/15/2022 2019-915
United States Of America Published Application 2022028980 09/15/2022 2019-915
 

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Goldstein, Steven A.N.

Other Information

Categorized As


5270 California Avenue / Irvine,CA
92697-7700 / Tel: 949.824.2683
  • Facebook
  • Twitter
  • Twitter
  • Twitter
  • Twitter